Esanex Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Esanex General Information
Description
Developer of an oncology drug intended to offer insights into the role of heat shock protein inhibitors as important anti-cancer agents. The company's drug providesdurable clinical responses in Phase 1b trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors (NET), enabling caregivers to block multiple signaling pathways resulting in improved outcomes for patients.
Contact Information
Website
www.esanexpharma.comCorporate Office
- 115 West Washington Street
- Suite 1680, South Tower
- Indianapolis, IN 46204
- United States
Corporate Office
- 115 West Washington Street
- Suite 1680, South Tower
- Indianapolis, IN 46204
- United States
Esanex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 01-Jul-2019 | Completed | Out of Business | |||
| 2. Later Stage VC (Series A) | 10-Apr-2017 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 10-Dec-2012 | $15.5M | $15.5M | Completed | Clinical Trials - Phase 1 |
Esanex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Esanex Patents
Esanex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11492518-B2 | Self-adhesive composition for the bonding of substrates with low surface energy | Active | 28-Oct-2016 | ||
| US-20190256745-A1 | Self-adhesive composition for the bonding of substrates with low surface energy | Active | 28-Oct-2016 | ||
| AU-2017331441-A1 | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer | Inactive | 23-Sep-2016 | ||
| CA-3038064-A1 | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer | Inactive | 23-Sep-2016 | ||
| EP-3515436-A1 | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer | Inactive | 23-Sep-2016 | A61K31/416 |
Esanex FAQs
-
When was Esanex founded?
Esanex was founded in 2011.
-
Where is Esanex headquartered?
Esanex is headquartered in Indianapolis, IN.
-
What industry is Esanex in?
Esanex’s primary industry is Drug Discovery.
-
Is Esanex a private or public company?
Esanex is a Private company.
-
What is Esanex’s current revenue?
The current revenue for Esanex is .
-
How much funding has Esanex raised over time?
Esanex has raised $18.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process